Darentang: Net profit of 2.13 billion yuan in 2025, with the transfer of joint venture equity making a significant contribution to current period income.

2026-03-31 10:23:51

Abstract generation in progress

Recently, Daren Tong released its 2025 annual report. The company’s operating revenue was 4.92 billion yuan, down 32.7% year over year; net profit attributable to the parent company was 2.13 billion yuan, down 4.4% year over year; non-recurring items after excluding attributable net profit was 795 million yuan, up 6.6% year over year; net operating cash flow was 461 million yuan, down 50.1% year over year; EPS (fully diluted) was 2.7672 yuan.

In the company’s operating business during 2025, its business mainly centers on modern traditional Chinese medicine, covering medicinal material cultivation, pharmaceutical R&D, manufacturing, and operations, forming a complete healthcare and wellness industry chain in pharmaceuticals. During the reporting period, the company focused on cultivating products in core categories such as cardiovascular, cerebrovascular, and respiratory segments, and drove innovation and diversification in its sales model, including multi-channel arrangements such as self-operated retail, medical agency, and e-commerce.

In the management discussion and analysis, the company mentioned that it completed the divestment of its pharmaceutical commercial segment; therefore, related revenue is no longer recognized during the reporting period. In addition, in 2025 the company transferred 12% of the equity in Sinopharm Tianjin Sincere Pharmaceutical Co., Ltd., achieving an after-tax net gain of 1.308 billion yuan, which made a significant contribution to the company’s profit for the period. These changes had an important impact on the company’s operating results and revenue structure. The management stated that it will continue to extend its layout around green traditional Chinese medicine and expand businesses such as TCM diagnosis and treatment and health technology.

(Daren Tong announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.